ZA201606252B - Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators - Google Patents

Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators

Info

Publication number
ZA201606252B
ZA201606252B ZA2016/06252A ZA201606252A ZA201606252B ZA 201606252 B ZA201606252 B ZA 201606252B ZA 2016/06252 A ZA2016/06252 A ZA 2016/06252A ZA 201606252 A ZA201606252 A ZA 201606252A ZA 201606252 B ZA201606252 B ZA 201606252B
Authority
ZA
South Africa
Prior art keywords
chromene
pyridopyrazinediones
tetrahydrocyclopropa
gamma
secretase modulators
Prior art date
Application number
ZA2016/06252A
Other languages
English (en)
Inventor
Ende Christopher William Am
John Michael Humphrey
Douglas Scott Johnson
Gregory Wayne Kauffman
Martin Youngjin Pettersson
Danica Antonia Rankic
Antonia Friederike Stepan
Patrick Robert Verhoest
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52815058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201606252(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of ZA201606252B publication Critical patent/ZA201606252B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA2016/06252A 2014-04-01 2016-09-09 Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators ZA201606252B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461973436P 2014-04-01 2014-04-01
PCT/IB2015/051988 WO2015150957A1 (en) 2014-04-01 2015-03-18 Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators

Publications (1)

Publication Number Publication Date
ZA201606252B true ZA201606252B (en) 2018-05-30

Family

ID=52815058

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2016/06252A ZA201606252B (en) 2014-04-01 2016-09-09 Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators

Country Status (29)

Country Link
US (2) US20150274721A1 (enExample)
EP (1) EP3126361B1 (enExample)
JP (1) JP6643247B2 (enExample)
KR (1) KR101886945B1 (enExample)
CN (1) CN106211770B (enExample)
AP (1) AP2016009465A0 (enExample)
AR (1) AR099874A1 (enExample)
AU (1) AU2015242330B2 (enExample)
BR (1) BR112016022519A8 (enExample)
CA (1) CA2944308A1 (enExample)
CL (1) CL2016002422A1 (enExample)
CR (1) CR20160454A (enExample)
CU (1) CU20160140A7 (enExample)
DK (1) DK3126361T3 (enExample)
DO (1) DOP2016000266A (enExample)
EA (1) EA031419B1 (enExample)
EC (1) ECSP16078289A (enExample)
ES (1) ES2759277T3 (enExample)
IL (1) IL248154B (enExample)
MD (1) MD20160102A2 (enExample)
MX (1) MX369074B (enExample)
NI (1) NI201600149A (enExample)
PE (1) PE20161364A1 (enExample)
PH (1) PH12016501864A1 (enExample)
SG (1) SG11201607465UA (enExample)
TW (1) TWI568733B (enExample)
UY (1) UY36054A (enExample)
WO (1) WO2015150957A1 (enExample)
ZA (1) ZA201606252B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
CN107406445B (zh) * 2015-02-03 2019-12-24 辉瑞公司 新颖环丙苯并呋喃基吡啶并吡嗪二酮类
CN106580997B (zh) * 2016-12-09 2018-01-19 张田 一种治疗先兆流产的药物组合物
IL267253B2 (en) 2016-12-16 2023-04-01 Pipeline Therapeutics Inc Methods for treating cochlear synaptopathy
KR20230170813A (ko) * 2018-09-12 2023-12-19 노파르티스 아게 항바이러스 피리도피라진디온 화합물
CN110907542A (zh) * 2018-09-17 2020-03-24 复旦大学 一种液质联用检测唾液中司来吉兰及其代谢物的方法
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN113543852A (zh) 2019-03-06 2021-10-22 第一三共株式会社 吡咯并吡唑衍生物
WO2021061898A1 (en) 2019-09-26 2021-04-01 Novartis Ag Antiviral pyrazolopyridinone compounds
AU2023364628A1 (en) 2022-10-18 2025-04-03 Pfizer Inc. Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers
WO2024084363A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Use of patatin-like phospholipase domain-containing protein 3 compounds

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE239797T1 (de) 1993-01-25 2003-05-15 Takeda Chemical Industries Ltd Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
DE69839808D1 (de) 1997-04-09 2008-09-11 Intellect Neurosciences Inc Für die termini des beta-amyloids spezifische, rekombinante antikörper, dafür kodierende dna und verfahren zu ihrer verwendung
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
CZ304211B6 (cs) 2000-02-24 2014-01-08 Washington University Humanizovaná protilátka, její fragment a jejich použití, polynukleová kyselina, expresní vektor, buňka a farmaceutický prostředek
DE10045112A1 (de) 2000-09-11 2002-03-21 Merck Patent Gmbh Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems
EP1335738A4 (en) 2000-11-03 2004-09-08 Proteotech Inc METHOD FOR ISOLATING AMYLOID-INHIBITING COMPOUNDS AND USE OF COMPOUNDS ISOLATED FROM UNCARIA TOMENTOSA AND RELATED PLANTS
CA2451998A1 (en) 2001-08-17 2003-02-27 Eli Lilly And Company Anti-a.beta. antibodies
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
KR101030629B1 (ko) * 2002-02-28 2011-04-20 미쯔비시 웰 파마 가부시키가이샤 헤테로아릴 치환된 2-피리디닐 및2-피리미디닐-6,7,8,9-테트라히드로피리미도[1,2-a]피리미딘-4-온 유도체
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
US20040146512A1 (en) 2002-10-09 2004-07-29 Arnon Rosenthal Methods of treating Alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
CA2528652A1 (en) 2003-06-19 2004-12-23 Pfizer Products Inc. Nk1 antagonist
EP1666061A1 (en) 2003-09-09 2006-06-07 Takeda Pharmaceutical Company Limited Use of antibody
GB0327319D0 (en) 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
CA2555071A1 (en) 2004-02-02 2005-09-01 Pfizer Products Inc. Histamine-3 receptor modulators
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
EA016357B1 (ru) 2004-07-30 2012-04-30 Ринат Ньюросайенс Корп. Антитела, направленные против бета-амилоидного пептида, и способы их применения
GB0423356D0 (en) 2004-10-21 2004-11-24 Merck Sharp & Dohme Therapeutic agents
EP1827493A4 (en) 2004-12-22 2009-09-30 Univ St Louis USE OF ANTI-ABETA ANTIBODIES FOR THE TREATMENT OF BRAIN TRAUMA
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
AU2006245416B2 (en) 2005-05-12 2012-02-23 Pfizer Inc. Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
WO2006126083A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors
CA2603830A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Co Llc PYRIDINE [2,3-B] PYRAZINONES
WO2006126082A2 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
ATE488496T1 (de) 2005-06-22 2010-12-15 Pfizer Prod Inc Histamin-3-rezeptorantagonisten
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
JP2009514846A (ja) 2005-11-04 2009-04-09 ファイザー・リミテッド テトラヒドロナフチリジン誘導体
WO2007063385A2 (en) 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
WO2007069053A1 (en) 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
WO2007088462A1 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Spirochromane antagonists of the h-3 receptor
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
WO2007105053A2 (en) 2006-03-13 2007-09-20 Pfizer Products Inc. Tetralines antagonists of the h-3 receptor
EP2013208B1 (en) 2006-04-21 2011-06-22 Pfizer Products Inc. Pyridin[3,4-b]pyrazinones
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
BRPI0806473A2 (pt) 2007-01-22 2011-09-27 Pfizer Prod Inc sal de tosilato de um composto terapêutico e composições farmacêuticas do mesmo
JP2012506857A (ja) * 2008-10-23 2012-03-22 メルク・シャープ・エンド・ドーム・コーポレイション 縮合複素環式m1受容体ポジティブアロステリック調節因子
JP5767393B2 (ja) * 2011-03-31 2015-08-19 ファイザー・インク 新規二環式ピリジノン
ES2585009T3 (es) * 2012-05-16 2016-10-03 Janssen Pharmaceuticals, Inc. Derivados de 3,4-dihidro-2H-pirido[1,2-a]pirazina-1,6-diona sustituidos útiles para el tratamiento de (inter alia) enfermedad de Alzheimer
UA110688C2 (uk) * 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
AU2014206834B2 (en) * 2013-01-17 2017-06-22 Janssen Pharmaceutica Nv Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators
ES2742078T3 (es) * 2013-10-04 2020-02-13 Pfizer Piridonas bicíclicas novedosas como moduladores de gamma-secretasa

Also Published As

Publication number Publication date
US20150274721A1 (en) 2015-10-01
JP6643247B2 (ja) 2020-02-12
PE20161364A1 (es) 2016-12-25
AR099874A1 (es) 2016-08-24
JP2017512803A (ja) 2017-05-25
PH12016501864A1 (en) 2016-12-19
WO2015150957A1 (en) 2015-10-08
CR20160454A (es) 2016-12-06
DK3126361T3 (da) 2020-01-02
BR112016022519A2 (pt) 2017-08-15
ES2759277T3 (es) 2020-05-08
MD20160102A2 (ro) 2017-04-30
ECSP16078289A (es) 2017-02-24
TWI568733B (zh) 2017-02-01
US20170166566A1 (en) 2017-06-15
AU2015242330A1 (en) 2016-09-22
NI201600149A (es) 2016-11-18
HK1231481A1 (zh) 2017-12-22
MX2016012904A (es) 2016-12-07
AU2015242330B2 (en) 2017-08-17
MX369074B (es) 2019-10-28
CN106211770A (zh) 2016-12-07
AP2016009465A0 (en) 2016-09-30
EP3126361B1 (en) 2019-11-06
CA2944308A1 (en) 2015-10-08
EP3126361A1 (en) 2017-02-08
KR101886945B1 (ko) 2018-08-08
CU20160140A7 (es) 2017-02-02
CN106211770B (zh) 2018-02-06
UY36054A (es) 2015-10-30
SG11201607465UA (en) 2016-10-28
EA201600619A1 (ru) 2017-03-31
TW201540716A (zh) 2015-11-01
IL248154A0 (en) 2016-11-30
BR112016022519A8 (pt) 2018-03-06
KR20160137635A (ko) 2016-11-30
EA031419B1 (ru) 2018-12-28
DOP2016000266A (es) 2016-11-15
IL248154B (en) 2020-09-30
CL2016002422A1 (es) 2017-02-03

Similar Documents

Publication Publication Date Title
IL248154A0 (en) Derivatives of chromane and 7b, 2, 1a, 1-tetrahydrocycloprop-c-chromane pyridopyrazinedione and their use for gamma-secretase modulation
EP3180067A4 (en) Disnfectant caps
EP3212021A4 (en) In-mold rotation helmet
IL247847B (en) ror gamma modulator and their use
EP3206696A4 (en) Multiplexed shrnas and uses thereof
EP3144243A4 (en) Cap
PT3397702T (pt) Tinta piezorresistiva, métodos e utilizações da mesma
ZA201702720B (en) 1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds and use as sgrm modulators
EP3128038A4 (en) Hot-stamping steel material
EP3212633A4 (en) Potent gamma-secretase modulators
EP3166945A4 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
EP3134310A4 (en) Crawler-track unit and forest machine
EP3094798A4 (en) Padlock cylinder retention
GB201421408D0 (en) An agrochemical composition, a method of preparing the same and the use thereof
GB2537106B (en) A novel form of rimsulfuron, a process for its preparation and use of the same
EP3194628A4 (en) Antisense compounds and uses thereof
EP3176124A4 (en) Crane
LT3149002T (lt) 5-oksa-2-azabiciklo[2.2.2]oktan-4-ilo ir 5-oksa-2-azabiciklo[2.2.1]heptan-4-ilo dariniai kaip taar1 moduliatoriai
ZA201803520B (en) Indane derivatives as mglur7 modulators
EP3194591A4 (en) Antisense compounds and uses thereof
EP3101644A4 (en) Dental-pulp-cavity model
PL3122184T3 (pl) Mikrokapsułki chlomazonu, ich wytwarzanie i zastosowanie
PL3105243T3 (pl) Pochodne 2',3'-dideoksy-5-fluorourydyny, sposób ich wytwarzania i zastosowanie
EP3166946A4 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
ZA201606656B (en) Ror-gamma modulators and uses thereof